

Index

- AAI. *See* Age-at-interview (AAI)
 ADHD. *See* Attention-Deficit Hyperactivity Disorder (ADHD)
 AG. *See* Agoraphobia (AG)
 age-at-interview (AAI), 63
 age-of-onset (AOO), 19, 21, 24, 42, 58, 84, 107, 121, 134, 153, 232, 234, 250, 264, 287, 289, 292, 293, 328–329
 AG, 107
 alcohol use disorders (AUDs), 232, 233
 bulimia nervosa and binge eating disorder, 267, 268
 bipolar spectrum disorder (BPD), 58–63
 drug use disorders, 253, 370
 generalised anxiety disorder (GAD), 84
 intermittent explosive disorder (IED), 184
 major depressive disorder (MDD), 46, 337
 oppositional defiant disorder (ODD) and conduct disorder (CD), 213, 214
 panic attacks (PAs), 99, 102
 panic disorder (PD), 346
 posttraumatic stress disorder (PTSD), 157, 158
 social anxiety disorder (SAD), 121, 124, 125
 separation anxiety disorder (SEPAD), 169, 172, 173
 specific phobia, 140
 aggression, 182
 aggressiveness, 183
 agoraphobia (AG), 106. *See also* *Specific phobia*
 age at selected percentiles, 110, 349
 age-of-onset, 107
 comorbidity, 113–117
 DSM-IV AG, 117
 epidemiology of, 106
 as independent disorder, 118
 method, 106–107
 persistence, 107
 prevalence, 107, 118
 of agoraphobia in World Mental Health surveys, 108–109
 without panic disorder in World Mental Health surveys, 347, 348
 role impairment, 107–113
 severity of role impairment, 111–112, 350
 socio-demographic correlates, 113, 114–115
 treatment, 113
 agoraphobic fears, 106
 alcohol abuse (ALA), 186, 223, 224
 average lifetime prevalence rate, 232
 onset, 205
 alcohol dependence (ALD), 223, 224
 average lifetime prevalence rate, 232
 alcohol-use disorders (AUDs), 223, 244. *See also* *Oppositional defiant disorder (ODD)*; *Posttraumatic stress disorder (PTSD)*
 AOO, 232, 234
 average lifetime prevalence of, 239
 categories, 223
 comorbidity, 234, 237
 concept and diagnostic criteria for, 240
 differences in, 239
 methods, 225
 persistence, 232–234
 prevalence, 224, 225–231
 role impairment, 234, 237
 socio-demographic correlates, 234, 235–236
 treatment, 234–239
 ALD. *See* Alcohol dependence (ALD)
 American Psychiatric Association (APA), 209
 amphetamines, 243
 AN. *See* Anorexia nervosa (AN)
 analysis weights, construction of, 16–18
 anger, 182
 attacks, 183, 184, 186
 animal fear, 136
 Annual Reports Questionnaire (ARQ), 243
 anorexia nervosa (AN), 2, 263
 anxiety, 120
 disorders, 93, 324
 AOO. *See* Age-of-onset (AOO)
 APA. *See* American Psychiatric Association (APA)
 area probability methods, 14
 ARQ. *See* Annual Reports Questionnaire (ARQ)
 Attention-Deficit Hyperactivity Disorder (ADHD), 195, 297. *See also* *Alcohol-use disorders (AUDs)*; *Posttraumatic stress disorder (PTSD)*
 ADHD Clinical Diagnostic Scale (ACDS), 196
 adult, 203
 impairments in, 205–206
 multiple imputation strategy to arrive at, 195–196
 treatment, 201–203, 206
 age, 205
 childhood, 203
 comorbidity, 199, 201
 diagnostic assessment, 195
 disability, 199, 201
 multiple imputation strategy, 195–196
 prevalence in childhood and persistence into adulthood, 196, 197, 201
 socio-demographic correlates of, 196, 198–199
 threshold and subthreshold childhood, 204
 AUDs. *See* Alcohol-use disorders (AUDs)
 Australian National Survey of Mental Health and Well-being (NSMHWB), 106
 Balanced Repeated Replication method, 18
 BED. *See* Binge-eating disorder (BED)
 bi-directional associations between PEs and mental disorders, 293–294
 bifactor models, 300
 binge-eating disorder (BED), 103, 263. *See also* *Drug-use disorders (DUD)*; *Mental disorders*
 AOO and persistence, 264, 267, 268
 associations with BMI, 264
 comorbidity, 267–268, 275, 276
 impairment in role attainment and role functioning, 264, 266, 269, 270
 method, 263–264
 prevalence, 264, 265, 266
 socio-demographic correlates, 266–267, 271–272, 273–274
 treatment, 268, 275–276, 277–280
 bipolar disorder (BPD), 57, 300. *See also* *Generalized anxiety disorder (GAD)*; *Major depressive disorder (MDD)*; *Panic Disorder (PD)*
 age at selected percentiles on standardized age-of-onset, 61–62
 AOO, 58–63
 BP-I disorder, 57
 BP-II disorder, 57
 comorbidity, 67
 comparative frequency-intensity of manic, hypomanic, and depressive episodes, 66–67
 complete model with, 306, 308–310
 method, 58
 placement, 304
 prevalence, 58
 prevalence of DSM-IV bipolar spectrum disorder, 59–60
 rapid cycling, 66
 role impairment, 67–69

Index

- bipolar disorder (BPD) (*cont.*)
 severity of role impairment, 70–71
 socio-demographic correlates, 63–66
 treatment, 69–74
 12-month bipolar spectrum disorder, 72–73
- bipolar mood disorders, 82
- bipolar spectrum disorder, 57, 58
 bivariate associations between socio-demographics correlates and DSM-IV, 64–65
 comorbidity, 68
 30-day prevalence, 63
- bivariate associations
 between socio-demographic correlates and DSM-IV oppositional defiant disorder, 375, 376, 377
 and DSM-IV posttraumatic stress disorder, 362–363
 and DSM-IV social anxiety disorder, 352–353, 354–355
 and posttraumatic stress disorder, 364–365, 366–367
 time-lagged, 67
- BMI. *See* Body-Mass Index (BMI)
- BN. *See* Bulimia nervosa (BN)
- body-mass index (BMI), 264
- BPD. *See* Bipolar disorder (BPD)
- bulimia nervosa (BN), 263, 328
 AOO and persistence, 264, 267, 268
 associations with BMI, 264
 comorbidity, 267–268, 275, 276
 impairment in role attainment and role functioning, 264, 266, 269, 270
 method, 263–264
 prevalence, 264, 265, 266
 socio-demographic correlates, 266–267, 271–272, 273–274
 treatment, 268, 275–276, 277–280
- Burdens of Mental Disorders, The*, 69
- CAM sector. *See* Complementary-alternative medical sector (CAM sector)
- cannabis, 243, 245
- CAPI. *See* Computer-assisted personal interview (CAPI)
- case-control sampling, 34
- CCP. *See* Clinical contact person (CCP)
- CD. *See* Conduct disorder (CD)
- centralized screening procedures, 29
- CFAs. *See* Confirmatory factor analyses (CFAs)
- CFI. *See* Comparative Fit Index (CFI)
- child SEPAD, 169
- childhood
 ADHD prevalence and persistence into adulthood, 196, 197, 201, 203
 childhood-onset disorders, 219
- CI. *See* Confidence interval (CI)
- CIDI. *See* Composite International Diagnostic Interview (CIDI)
- clinical characteristics, likelihood of receiving treatment across service sectors by, 315, 317
- clinical contact person (CCP), 30
- cocaine, 243, 245
- combining strategies, 24–25
- common disorders, complete model with, 306, 308–310
- common mental disorders, 301–304
- community surveys methodology, 4
- community-based surveys, 286
- comorbidity, 67, 113–117, 254, 257, 297, 330–331
 of ADHD with other mental disorders, 199, 201
 among disorders, 34–35
 analyses, 80
 AUDs, 234, 237
 bipolar spectrum disorder, 68
 of DSM-IV and DSM-5 generalized anxiety disorder, 83
 GAD, 82
 of major depressive disorder, 45, 46
 with mental disorders, 267
 of binge-eating disorder with hierarchy with DSM-IV disorders, 275
 of bulimia nervosa with DSM-IV disorders, 276
 in ODD and CD, 215–218
 with other DSM-IV disorders, 186–187, 190
 of PTSD, 158–162
 SAD, 128, 131
 specific phobia, 140, 144–145
- Comparative Fit Index (CFI), 301
- comparative frequency-intensity of manic, hypomanic, and depressive episodes, 66–67
- complementary-alternative medical (CAM) sector, 27, 239, 257, 315
- complex designs, 18, 19
- complex sample designs for WMH surveys, 13–14
- Composite International Diagnostic Interview (CIDI), 4, 9, 21, 25, 41, 80, 106, 153, 168, 183, 287
 CIDI Version 3.0, 27, 29, 80, 121, 195, 225
 module for SEPAD, 169
 symptom, 263–264
 translations, 28
- computer-assisted personal interview (CAPI), 28
- condition-specific SDS scales, 27
- conduct disorder (CD), 209, 297
 age-of-onset for ODD and, 213, 214
 during childhood, 209
 comorbidity, 215–218
 cross-national lifetime prevalence estimates, 218
 epidemiological studies, 210
 epidemic and treatment, 218
 methods, 210
 persistence, 214–215
 prevalence, 211–212
 prevalence, course, and correlates of, 209–210
 socio-demographic correlates, 215–217
 use of multiple informants, 219
- confidence interval (CI), 18, 33, 63
- configural invariance, 299, 301, 302, 311
- confirmatory factor analyses (CFAs), 300
- contemporary psychiatric nosology and epidemiology, criticisms of, 5–7
- contingent feedback approach, 23
- contingent reinforcement, 23
- Cox proportional hazards analysis approach, 33
- cross-disorder perspective, 324
- cross-national
 analyses, 301
 datasets, 300–301
 mental disorders, 300
 bivariate associations of lifetime mental disorders, 298
 common mental disorders, 301–304
 community surveys methodology, 4
 complete model with common disorders, PEs and bipolar disorder, 306, 308, 309, 310
 criticisms of contemporary psychiatric nosology and epidemiology, 5–7
 differences, 33
 epidemiology of mental disorders, 3
 global collaborative research networks, 5
 lifetime prevalence of CD, 211
 operationalization of mental disorders, 3–4
 pattern, 328
 perspective, 324
 placement
 bipolar disorders, 304
 eating disorders, 305
 IED, 305–306
 psychotic experiences, 306, 307, 308
 prevalence, 287–289
 scoring system, 26
 structure of mental disorders, 297
- cultural adaptation of survey methods, 29
- cumulative AOO distributions of PEs, 293
- cumulative lifetime probability curves, 31, 32
- cumulative lifetime probability distributions, estimating, 31
- DALYs. *See* Disability-adjusted Life Years (DALYs)
- datasets, 300–301
- defensive aggression, 182
- delusional experiences (DEs), 286
- depression, 120, 182
- depressive disorder, 338–339, 340–341
- DEs. *See* Delusional experiences (DEs)
- design effect, 18, 19, 20
- Diagnostic and Statistical Manual of Mental Disorders (DSM)*, 3, 120
 DSM-defined specific phobia, 134
 DSM-III diagnosis, 120
 DSM-IV and DSM-5, 3
 DSMIV-TR, 223
- diagnostic assessment, 195
- diagnostic criteria, 3, 4, 6
 for CD, 210
 for ODD, 210
- Diagnostic Interview Schedule (DIS), 4, 195, 224

- disability-adjusted life years (DALYs), 223
discrete-time survival analysis, 33
disorder
 disorder-specific analyses, 34–35
 interaction between disorder
 severity and socio-demographic characteristics, 319
 persistence, 107, 136, 232–234, 250
 ‘double sampling’ technique, 13
drug abuse (DRA), 243
drug dependence (DRD), 243
drug-use disorders (DUD), 225, 243. *See also* Binge-eating disorder (BED); Mental disorders
 AOO, 250, 253
 comorbidity, 254, 257
 demographics, 254, 255–256
 methods, 244–245
 persistence, 250
 prevalence, 245
 of DSM-IV drug abuse in WMH surveys, 246–247
 of DSM-IV drug dependence in WMH surveys, 248–249
 of DSM-IV drug-use disorder in WMH surveys, 251
 12-month prevalences of DRA and DRD, 250
 role impairment, 250, 254
 treatment, 257–258
DSM. *See* Diagnostic and Statistical Manual of Mental Disorders (DSM)
DSM-IV. *See* Fourth Edition of the Diagnostic and Statistical Manual (DSM-IV)
DUD. *See* Drug-use disorders (DUD)
dysfunctional exaggeration, 167

Eastern Mediterranean region, 239
eating disorders, 263, 267, 305, 324
 IED and, 306
 incidence, 281
 lifetime treatment of, 275
 placement, 305
ECA. *See* Epidemiological Catchment Area Study (ECA)
educational status, 25–26
EFA. *See* Exploratory factor analyses (EFA)
Epidemiological Area Catchment Study (ECA), 49, 94
episode persistence, 107
episodic memory, 23
European Study of the Epidemiology of Mental Disorders (ESEMED), 42
exploratory factor analyses (EFA), 301
externalizing
 domains, 297
 factor, 299

Feighner criteria, 3, 4
FME. *See* Frequent mood episodes (FME)
four-stage designs, 14
Fourth Edition of the Diagnostic and Statistical Manual (DSM-IV), 1, 9, 106, 153, 168
 AG, 117

age at selected percentiles on standardized age-of-onset distributions of PD, 346
bivariate associations between socio-demographic correlates and SAD, 352–355, 356–357
BN criteria, 263–264
comorbidity, 177, 178
comorbidity of specific phobia with other disorders, 360
criterion A for IED, 183
criterion B for IED, 183
criterion C for IED, 183
MDD, 42
‘free-floating’ anxiety, 79
frequent mood episodes (FME), 66

GAD. *See* Generalized anxiety disorder (GAD)
GBD study. *See* Global Burden of Disease study (GBD study)
general interviewing training (GIT), 29–30
general medical sector, 27
generalized anxiety disorder (GAD), 4, 27, 79, 324. *See also* Bipolar disorder (BPD); Major depressive disorder (MDD); Panic Disorder (PD)
 bivariate associations of socio-demographic variables, 87–88
 comorbidity, 82
 course and correlates, 84–86
 DSM-IV conceptualization of, 79
 help-seeking samples, 80
 methods, 80
 prevalence, 80–82
 role impairment, 82
 treatment, 82, 85, 84, 90
GIT. *See* General interviewing training (GIT)
Global Burden of Disease study (GBD study), 5, 243, 326
global collaborative research networks, 5
global mental health, 5

hallucinatory experiences (HEs), 286
Harvard Medical School (HMS), 16
HD. *See* Hyperactivity-impulsivity (HD)
help-seeking samples, 80
heroin, 243
HEs. *See* Hallucinatory experiences (HEs)
hierarchical coding scheme, 25
high-income countries, 356, 366, 377
higher-order model with bipolar disorder, 304
HMS. *See* Harvard Medical School (HMS)
human services sector, 27
hyperactivity-impulsivity (HD), 195
hypomanic episodes, comparative frequency-intensity of, 66–67

ICD. *See* International Statistical Classification of Diseases (ICD)
ICPE. *See* International Consortium in Psychiatric Epidemiology (ICPE)
IED. *See* Intermittent explosive disorder (IED)

impairment
 role, 67–69, 107–113, 184, 250, 254
 attainment and role functioning, 264, 266
 severity of role impairment associated with 12-month binge-eating disorder, 269
 associated with 12-month bulimia nervosa, 270
 in specific phobia, 135, 141, 146–147, 148
 and treatment of ODD and CD, 218
impulsive aggression, 182
Institute for Social Research (ISR), 9–10
inter-quartile range (IQR), 58, 107, 184
intermittent explosive disorder (IED), 182, 187, 324. *See also* Alcohol-use disorders (AUDs); Attention-Deficit Hyperactivity Disorder (ADHD); Posttraumatic stress disorder (PTSD)
 age-of-onset, 184
 associations of traumatic events with onset of IED, 187, 191
 comorbidity, 186–187, 190
 in DSM-IV, 182
 lifetime prevalence, 187, 190
 median age-of-onset, 191
 method, 183–184
 placement, 305–306
 prevalence, 184, 185, 192
 role impairment, 184, 186
 socio-demographic correlates, 186, 188–189
 treatment, 187
 type of anger attacks in past 12 months, 184, 186
internalizing disorders, 299
internalizing domains, 297
International Consortium in Psychiatric Epidemiology (ICPE), 5
International Statistical Classification of Diseases (ICD), 3, 4, 118, 120
 ICD-10, 9
interviewer training, 29
 interviewer hiring and training, 29–30
 and quality control monitoring, 28, 30
IQR. *See* Inter-quartile range (IQR)
ISR. *See* Institute for Social Research (ISR)

Jackknife Repeated Replication method (JRR method), 18

lifetime
 comorbidity, 177, 178
 prevalence, 30–31, 107
 IED, 187, 190
 of PTSD, 154
likelihood of receiving treatment across
 by clinical characteristics, 315, 317
 by socio-demographic characteristics, 315, 318–319
logistic link function, 34
logistic regression analysis, 17
low and middle-income countries, 5

Index

- low/lower-middle-income countries, 352–353, 362–363, 375
 lower bound estimates, 31
- major depression, 26, 27, 41, 55, 58, 282, 330
 major depressive disorder (MDD), 41, 79, 324. *See also* Bipolar disorder (BPD); Generalized anxiety disorder (GAD); Panic Disorder (PD)
 age-of-onset distributions of DSM-IV MDD, 337
 AOO and projected lifetime risk of, 46
 bivariate associations between socio-demographics, 52–53
 comorbidity of major depressive disorder, 45, 46
 method, 42
 prevalence and persistence, 42–46
 role impairment, 46–49
 socio-demographic correlates, 49–54
 socio-economic factors, 41
 treatment, 49
 12-month major depressive disorder, 50–51
 manic episodes, comparative frequency-intensity of, 66–67
 marital separation/divorce, 190
 marital status, 25
 MDD. *See* Major depressive disorder (MDD)
 median age-of-onset, IED, 191
 mental disorders, 19, 182, 244, 287, 297, 300, 324. *See also* Binge-eating disorder (BED); Bipolar disorder (BPD); Drug-use disorders (DUD); Generalized anxiety disorder (GAD)
 ability to answer accurately, 23–24
 bi-directional association between PEs and, 293–294
 combining strategies, 24–25
 comorbidity
 of ADHD with, 199, 201
 between disorders, 330–331
 cross-national epidemiology, 3–7
 impact, 329
 variation across countries, 329–330
 variation across disorders, 329
 life course, 328–329
 motivation, 22–23
 operationalization, 3–4
 persistence, 328
 policy implications, 331–332
 prevalence, 324
 variation across countries, 326–328
 variation across disorders, 324–326
 question comprehension, 21–22
 study limitations, 331
 task comprehension, 22
 mental health
 specialist sector, 27
 treatment gap, 314
 MG-CFA. *See* Multigroup-CFA (MG-CFA)
 MI. *See* Multiple imputation (MI)
- mood disorders, 82
 morbid risk, 31, 32
 motivation, 22–23
 multigroup-CFA (MG-CFA), 301
 multiple imputation (MI), 196
 to arriving at adult ADHD prevalence estimates, 195–196
 multivariate significance tests, 33
- National Comorbidity Study, 94, 134
 National Comorbidity Study Replication (NCS-R), 94, 153
 National Comorbidity Survey, 41
 National Epidemiological Survey on Alcohol and Related Conditions (NESARC), 94, 134
 National Institutes of Health in United States, 5
 NCS. *See* National Comorbidity Study (NCS)
 NCS-R. *See* National Comorbidity Study Replication (NCS-R)
 negative predictive value (NPV), 57
 NESARC. *See* National Epidemiological Survey on Alcohol and Related Conditions (NESARC)
 Netherlands Mental Health Survey and Incidence Initiative (NEMESIS), 134
 nonresponse
 adjustment weight, 16
 surveys, 15–16
 NPV. *See* Negative predictive value (NPV)
 NSMHWB. *See* Australian National Survey of Mental Health and Well-being (NSMHWB)
- obsessive compulsive disorder (OCD), 2, 297
 ODD. *See* Oppositional defiant disorder (ODD)
 odds-ratios (ORs), 33, 34, 63, 191, 199
 older mental-health studies, 299–300
 oppositional defiant disorder (ODD), 209, 297, 376. *See also* Alcohol-use disorders (AUDs); Attention-Deficit Hyperactivity Disorder (ADHD)
 age-of-onset for, 213, 214
 during childhood, 209
 comorbidity, 215–218
 cross-national lifetime prevalence estimates, 218
 epidemiological studies, 210
 impairment and treatment, 218
 methods, 210
 persistence, 214–215
 prevalence, 211–212
 prevalence, course, and correlates of, 209–210
 socio-demographic correlates, 215–217
 symptoms, 209
 use of multiple informants, 219
 ORs. *See* Odds-ratios (ORs)
 outcome variables, prevalence of, 30–31
- panic attacks (PAs), 93
 comorbidity of single and recurrent, 100–101
 prevalence and age-of-onset of types of, 102
 in WMHS
 30-day prevalence of, 344–345
 12-month prevalence of, 342–343
 panic disorder (PD), 93, 106. *See also* Bipolar disorder (BPD); Generalized anxiety disorder (GAD); Major depressive disorder (MDD)
 age at selected percentiles on standardized age-of-onset distributions
 of agoraphobia without, 349
 of DSM-IV, 346
 comorbidity and correlates, 95, 99
 epidemiology, 93–94, 106
 essential feature, 93
 lifetime prevalence of panic attack and DSM-IV, 96–97
 method, 94–95
 number and type of PAs, 99
 prevalence, 95
 role impairment and treatment, 95
 severity of role impairment, 98
 associated with 12-month agoraphobia without PD, 350–351
 in WMHS
 prevalence of agoraphobia without, 347, 348
 30-day prevalence, 344–345
 12-month prevalence, 342–343
 paper and pencil interview (PAPI), 28
 PAPI. *See* Paper and pencil interview (PAPI)
 PAs. *See* Panic attacks (PAs)
 PD. *See* Panic Disorder (PD)
 People's Republic of China (PRC), 121, 168
 persistence, 264
 of AG, 107
 AUDs, 232
 of ODD and CD, 214–215
 person-level analysis, 16
 person-year models, 33–34
 PEs. *See* Psychotic experiences (PEs)
 phobias, 120
 phobic stimulus, 134
 population registry approach, 13
 positive predictive value (PPV), 57
 poststratification
 factor, 17
 weighting step, 16
 posttraumatic stress disorder (PTSD), 26, 153, 315, 324. *See also* Attention-Deficit Hyperactivity Disorder (ADHD); Intermittent explosive disorder (IED); Separation anxiety disorder (SEPAD); Social anxiety disorder (SAD)
 age-of-onset, 157, 158
 bivariate associations between socio-demographic correlates and, 364–365, 366–367

- comorbidity, 158–162
 methods, 154
 prevalence, 154–157, 162, 164
 socio-demographic correlates, 157–158
 for associations with, 164
 TE exposure and, 162
 TE prevalence, 154
 treatment, 162
 12-month posttraumatic stress disorder, 163
 WMH surveys, 165
 PPV. *See* Positive predictive value (PPV)
 PRC. *See* People's Republic of China (PRC)
 premeditated aggression, 182
 pretesting, 28
 prevalence
 of agoraphobia in World Mental Health surveys, 108–109
 BPD, 58
 GAD, 80–82
 IED, 184, 185, 192
 MDD, 42–46
 of ODD and CD, 209–210, 211–212
 of PTSD, 154–157, 162, 164
 SEPAD, 169, 170–171
 specific phobia, 136–140
 probability sampling, 13
 psychiatric epidemiology, 1
 psychotic experiences (PEs), 286, 300
 age-of-onset, 289, 292, 293
 bi-directional association between PEs and mental disorders, 293–294
 complete model with, 306, 308–310
 methods, 287
 placement, 306, 307, 308
 prevalence, 287–289
 socio-demographic correlates, 289, 290–291
 PTSD. *See* Posttraumatic stress disorder (PTSD)
 quality assurance monitoring, 30
 quality control monitoring, 30
 question comprehension, 21–22
 rapid cycling, 66
 RDoC. *See* Research Domain Criteria (RDoC)
 Receiver Operating Characteristic (ROC) curve, 80
 resampling variance estimation methods, 18
 Research Diagnostic Criteria, 3, 4
 Research Domain Criteria (RDoC), 6, 7
 RMSEA. *See* Root Mean Square Error of Approximation (RMSEA)
 ROC curve. *See* Receiver Operating Characteristic curve (ROC curve)
 role impairment, 26–27, 46–49, 107–113, 250, 254
 associated with 12-month DSM-IV and DSM-5 generalized anxiety disorder, 84
 AUDs, 234, 237
 days-out-of-role due to 12-month specific phobia by, 360
 GAD, 82
 severity of, 47–48, 111–112
 Root Mean Square Error of Approximation (RMSEA), 301
 SA. *See* Separation anxiety (SA)
 SAD. *See* Social anxiety disorder (SAD)
 sample/sampling
 error, 18–19
 frames, 13
 selection weight, 16
 scalar invariance, 301
 schemas, 23
 schizophrenia, 286
 SCID. *See* Structured Clinical Interview for DSM-IV (SCID)
 SDS. *See* Sheehan Disability Scales (SDS)
 selection weight factor, 16
 semantic memory, 23
 SEPAD. *See* Separation anxiety disorder (SEPAD)
 separation anxiety (SA), 167
 separation anxiety disorder (SEPAD), 167, 177. *See also* Social anxiety disorder (SAD)
 adult, 168, 169, 324
 lifetime prevalence, 169
 role impairment, 172, 174
 12-month adult SEPAD, 179–180
 age-of-onset, 169, 172, 173
 in childhood, 179
 comorbidity, 177, 178
 concerns in adults, 168
 method, 168
 prevalence and persistence, 169, 170–171
 recall bias, 177
 socio-demographic correlates, 173, 175–176
 treatment, 177
 serious mental disorders, 3
 SES. *See* Socio-economic status (SES)
 Sheehan Disability Scales (SDS), 26, 46, 69, 141, 234, 315, 350, 371
 Sheehan impairment severity, 358–359, 361, 368–369, 373, 374
 simple random sampling (SRS), 18
 social anxiety, 132
 social anxiety disorder (SAD), 120, 297. *See also* Separation anxiety disorder (SEPAD)
 AOO, 121, 125
 comorbidity, 130, 131
 cross-national differences, 130
 with disability, 132
 in DSM-III, 120
 methods, 121
 phenomenology, 130
 prevalence, 121, 122–123
 role impairment, 121, 126–127
 socio-demographic correlates, 125, 128–129, 130
 treatment, 130
 12-month, 358–359
 WMH data on epidemiology of, 130
 social phobia, 120
 socio-demographic correlates,
 254, 266–267, 289
 ADHD, 196, 198–199
 AUDs, 234, 235–236
 bivariate associations
 and DSM-IV binge-eating disorder, 271–272
 and DSM-IV bulimia nervosa, 273–274
 DSM-IV oppositional defiant disorder, 377
 DSM-IV posttraumatic stress disorder and, 362–363, 364–365, 366–367
 DSM-IV social anxiety disorder and, 352–353, 354–355, 356–357
 and DSM-IV DUD, bivariate associations between, 255–256
 IED, 186, 188–189
 of lifetime disorders, 32–34
 of ODD and CD, 215–217
 of onset and persistence, 63–66
 of prevalence and persistence of AG, 113, 114–115
 of PTSD, 157–158
 SAD, 130
 SEPAD, 173, 175–176
 socio-demographic(s), 25–26
 associations, 49–54, 141
 bivariate associations between socio-demographic correlates, 290–291
 characteristics, 315, 318–319
 variables, 32
 socio-economic status (SES), 205
 socio-economic factors, 314
 special procedures, 30
 specific phobia, 134, 199. *See also* Agoraphobia (AG)
 age-of-onset, 140
 comorbidity, 140, 144–145
 of specific phobia with other DSM-IV disorders, 360
 days out of role due to 12-month specific phobia by role impairment, 360
 methods, 136
 onset of, 134
 prevalence and persistence, 136–140, 150
 role impairment, 135, 141, 146–147, 148
 socio-demographic correlates of onset, 140–141, 142–143
 socio-demographic correlates of persistence, 141
 subtypes, 135
 treatment, 148
 12-month, 361
 WMH surveys, 148
 SRC. *See* Survey Research Center (SRC)
 SRS. *See* Simple random sampling (SRS)
 standard programmes in statistical analysis
 software packages, 18
 statistical analysis methods, 30
 comorbidity among disorders, 34–35
 cumulative lifetime probability distribution estimation, 31–32
 decomposing socio-demographic correlates of 30-day prevalence, 34
 disorder-specific analyses, 35

Index

- statistical analysis methods (*cont.*)
 - prevalence of outcome variables, 30–31
 - socio-demographic correlates of lifetime disorders, 32–34
 - treatment of 12-month disorders, 35
- Structured Clinical Interview for DSM-IV (SCID), 80, 136, 169
- study-specific training, 30
- substance-use disorders (SUDS), 225
- subthreshold
 - BPD, 57
 - childhood ADHD, 204
- SUDS. *See* Substance-use disorders (SUDS)
- survey
 - cost structures, 13
 - population, 10
 - response rates, 14
- Survey Research Center (SRC), 10
- survivor bias, 54
- symptom persistence, 136, 140
- systematic monitoring, 30
- target populations, 10–13
- task comprehension, 22
- Taylor series linearization method, 18
- TE. *See* Traumatic event (TE)
- thirty-day prevalence, 31
 - decomposing socio-demographic correlating, 34
 - of PTSD, 157
- three-stage designs, 14
- threshold childhood ADHD, 204
- time-lagged associations between PEs and mental disorders, 294–295
- time-since-onset (TSO), 25, 63
- ‘train-the-trainer’ session, 29
- translation, 27–28
- traumatic event (TE), 153, 154
 - associations with onset of IED, 187, 191
 - categories, 154
 - prevalence, 154
- treatment/service use, 27, 49
 - methods, 314–315
 - type, 315, 316
 - interaction between disorder severity and socio-demographic characteristics, 319
 - likelihood of receiving treatment across service sectors, 315, 317
 - socio-demographic characteristics, 315, 318–319
- TSO. *See* Time-since-onset (TSO)
- 12-month/lifetime ratio, 289
- 12-month ADHD
 - adult ADHD treatment, 206
 - disability in, 199, 201
 - treatment of, 201–203
- 12-month prevalence, 31, 34
 - of CD, 211
 - of PTSD, 154
- 12-month treatment, 27, 35, 69, 203, 275
- two-part interview design, 14–15
- two-stage design, 13
- unbiasedness, 17
- unipolar mood disorders, 82
- United Nations Office on Drugs and Crime (UNODC), 243
- United States (US), 41, 94, 153
- universal health coverage, 332
- UNODC. *See* United Nations Office on Drugs and Crime (UNODC)
- unspecified bipolar disorder, 57
- upper-middle income countries, 354, 364, 376
- WDR. *See* World Drug Report (WDR)
- Weighted Least Squares
 - estimation for categorical data (WLSMV), 301
- weighting, 16
 - construction of analysis weights, 16–18
 - WMH poststratification, 17
- Westernized, educated, industrialized, rich, and democratic countries (WEIRD countries), 120
- WFS programme. *See* World Fertility Survey programme (WFS programme)
- WHO. *See* World Health Organization (WHO)
- WHO Disability Assessment Schedule (WHO-DAS), 199
- WLSMV. *See* Weighted Least Squares estimation for categorical data (WLSMV)
- WMH. *See* World Mental Health (WMH)
- World Drug Report (WDR), 243
- World Fertility Survey programme (WFS programme), 9
- World Health Organization (WHO), 1, 4, 9, 41, 168, 209, 223, 287, 314, 332
- World Mental Health (WMH), 1, 3, 5, 9, 41, 57, 80, 135, 168, 182, 223, 243–244, 263, 286, 314, 324
 - collaborators, 28
 - Data Collection Coordination Centre, 29
 - data on epidemiology of SAD, 132
 - interviewer training and quality control monitoring, 28–30
 - measures
 - mental disorders, 19–25
 - pretesting, 28
 - role impairment, 26–27
 - socio-demographics, 25–26
 - translation, 27–28
 - treatment/service use, 27
 - sampling, 9
 - characteristics by World Bank Income categories, 11–12
 - complex sample designs for WMH surveys, 13–14
 - error and inference from WMH survey data, 18–19
 - frames, 13
 - nonresponse surveys, 15–16
 - target populations, 10–13
 - two-part interview design, 14–15
 - weighting, 16–18
 - statistical analysis methods, 30–35
 - Surveys Initiative, 9
- YDLs. *See* Years lived with disability (YDLs)